CRBP

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Corbus Pharmaceuticals Holding

NASDAQ | CRBP

10.81

USD

$0.00

(

0.00%

)

At Close (As of Dec 1, 2025)

$202.56M

Market Cap

-

P/E Ratio

-5.49

EPS

$20.56

52 Week High

$4.64

52 Week Low

HEALTHCARE

Sector

CRBP Chart

Recent Chart
Price Action

CRBP Technicals

Tags:

CRBP Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$600K
Total Revenue $0
Cost Of Revenue $600K
Costof Goods And Services Sold $600K
Operating Income -$49M
Selling General And Administrative $16M
Research And Development $32M
Operating Expenses $48M
Investment Income Net -
Net Interest Income $4.4M
Interest Income $6.3M
Interest Expense $1.9M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $600K
Income Before Tax -$40M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$40M
Comprehensive Income Net Of Tax -
Ebit -$38M
Ebitda -$38M
Net Income -$40M

Revenue & Profitability

Earnings Performance

CRBP Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $156M
Total Current Assets $153M
Cash And Cash Equivalents At Carrying Value $17M
Cash And Short Term Investments $17M
Inventory -
Current Net Receivables -
Total Non Current Assets $2.9M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $132M
Other Current Assets $3.9M
Other Non Current Assets -
Total Liabilities $13M
Total Current Liabilities $12M
Current Accounts Payable $4.8M
Deferred Revenue -
Current Debt -
Short Term Debt $1.6M
Total Non Current Liabilities $1.6M
Capital Lease Obligations $3.2M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $3.2M
Other Current Liabilities $5.4M
Other Non Current Liabilities -
Total Shareholder Equity $142M
Treasury Stock -
Retained Earnings -$477M
Common Stock $1K
Common Stock Shares Outstanding $11M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$42M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -$2.7M
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$121M
Cashflow From Financing $167M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$40M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$600K
Total Revenue $0
Cost Of Revenue $600K
Costof Goods And Services Sold $600K
Operating Income -$49M
Selling General And Administrative $16M
Research And Development $32M
Operating Expenses $48M
Investment Income Net -
Net Interest Income $4.4M
Interest Income $6.3M
Interest Expense $1.9M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $600K
Income Before Tax -$40M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$40M
Comprehensive Income Net Of Tax -
Ebit -$38M
Ebitda -$38M
Net Income -$40M

CRBP News

CRBP Profile

Corbus Pharmaceuticals Holding Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology firm based in Norwood, Massachusetts, focused on developing groundbreaking therapies that target the endocannabinoid system. With a robust pipeline aimed at treating unmet medical needs in autoimmunity, fibrosis, and oncology, Corbus is well-positioned to transform chronic disease management and improve patient outcomes. Its unique cannabinoid-based treatment approach presents a compelling investment opportunity for institutional investors seeking to capitalize on innovative advancements within the healthcare landscape.

LPTX
+368.57%
$2.05
DRCT
+7.89%
$0.12
PAVS
-93.54%
$0.06
KALA
+67.68%
$1.62
NVDA
+1.50%
$179.65
HBI
-1.82%
$6.47
VINE
+21.21%
$0.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
FTEL
+38.78%
$1.17
BITF
-4.88%
$3.30
BYND
+23.24%
$1.21
AXDX
-61.36%
$0.03
IVP
+0.64%
$0.12
ASST
-7.14%
$1.04
PLUG
-1.99%
$1.97
ADAP
-15.14%
$0.05
AAL
+0.14%
$14.07
CHR
+4.57%
$0.04
BURU
-4.70%
$0.23
INTC
-1.54%
$39.93
BMNR
-11.76%
$29.22
SOND
-23.45%
$0.12
TLRY
-2.82%
$0.79
NFE
+13.77%
$1.38
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
NIO
-5.55%
$5.19
ADD
-25.47%
$0.05
TSLA
-0.02%
$430.06
SRM
+53.27%
$10.30
CNEY
-12.02%
$1.28
BMNU
+8.84%
$8.18
IRBT
+14.50%
$1.80
RPGL
+2.86%
$0.41
SOFI
-0.34%
$29.61
INHD
-23.53%
$0.17
ONDS
-2.91%
$7.67
MARA
-3.21%
$11.43
CLSK
-3.52%
$14.56
F
-0.26%
$13.24
YGMZ
-0.26%
$0.11
SNAP
+0.05%
$7.68
BTBT
-6.51%
$2.22
WLGS
-5.57%
$0.04
RIVN
+4.65%
$17.64
MTSR
-0.35%
$70.50
PFE
-1.61%
$25.32
CIFR
-1.40%
$20.06
BTG
-0.75%
$4.58
MSTR
-9.97%
$159.50
CAN
-6.40%
$0.94
AFMD
-34.94%
$0.18
SMX
+250.80%
$61.04
BBD
-1.62%
$3.64
DNN
0.00%
$2.56
ACHR
-2.24%
$7.61
AMZN
+0.86%
$235.24
HOOD
-4.60%
$122.57
IBRX
+10.79%
$2.36
PRPH
-5.55%
$0.19
RIG
+0.45%
$4.43
NWTN
-9.09%
$0.70
GRYP
-10.38%
$1.38
GOOGL
-0.87%
$317.36
NCT
-28.27%
$0.55
AMD
+0.99%
$219.68
MODV
-25.22%
$0.43
WULF
-0.85%
$15.37
RUBI
-11.59%
$0.14
PLTR
+0.13%
$168.68
SMR
+5.04%
$20.00
AG
+3.02%
$15.69
GRAB
-2.56%
$5.31
EXK
-4.28%
$9.50
T
+0.77%
$26.02
HBAN
+1.50%
$16.54
PLTD
+0.05%
$7.04
VHAI
-25.00%
$0.00
CRWV
+3.90%
$75.97
CPNG
-3.69%
$27.12
ITUB
-1.27%
$7.70
DVLT
-4.18%
$1.94
NFLX
+1.35%
$107.58
BAC
-0.18%
$53.55
APLD
+4.53%
$28.32
RGTI
-6.11%
$24.00
SAND
-6.04%
$12.12
BTE
+1.89%
$3.22
GPUS
-8.47%
$0.27
IREN
+0.37%
$47.99
HL
+5.32%
$16.82
VALE
+0.67%
$12.69
SHOT
-74.37%
$0.39
TE
+13.26%
$4.66
WBUY
+35.51%
$2.14
ZAPP
-46.30%
$0.15
CDE
-0.36%
$17.20
AAPL
+0.28%
$279.64
GOOG
-0.72%
$317.80
LPTX
+368.57%
$2.05
DRCT
+7.89%
$0.12
PAVS
-93.54%
$0.06
KALA
+67.68%
$1.62
NVDA
+1.50%
$179.65
HBI
-1.82%
$6.47
VINE
+21.21%
$0.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
FTEL
+38.78%
$1.17
BITF
-4.88%
$3.30
BYND
+23.24%
$1.21
AXDX
-61.36%
$0.03
IVP
+0.64%
$0.12
ASST
-7.14%
$1.04
PLUG
-1.99%
$1.97
ADAP
-15.14%
$0.05
AAL
+0.14%
$14.07
CHR
+4.57%
$0.04
BURU
-4.70%
$0.23
INTC
-1.54%
$39.93
BMNR
-11.76%
$29.22
SOND
-23.45%
$0.12
TLRY
-2.82%
$0.79
NFE
+13.77%
$1.38
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
NIO
-5.55%
$5.19
ADD
-25.47%
$0.05
TSLA
-0.02%
$430.06
SRM
+53.27%
$10.30
CNEY
-12.02%
$1.28
BMNU
+8.84%
$8.18
IRBT
+14.50%
$1.80
RPGL
+2.86%
$0.41
SOFI
-0.34%
$29.61
INHD
-23.53%
$0.17
ONDS
-2.91%
$7.67
MARA
-3.21%
$11.43
CLSK
-3.52%
$14.56
F
-0.26%
$13.24
YGMZ
-0.26%
$0.11
SNAP
+0.05%
$7.68
BTBT
-6.51%
$2.22
WLGS
-5.57%
$0.04
RIVN
+4.65%
$17.64
MTSR
-0.35%
$70.50
PFE
-1.61%
$25.32
CIFR
-1.40%
$20.06
BTG
-0.75%
$4.58
MSTR
-9.97%
$159.50
CAN
-6.40%
$0.94
AFMD
-34.94%
$0.18
SMX
+250.80%
$61.04
BBD
-1.62%
$3.64
DNN
0.00%
$2.56
ACHR
-2.24%
$7.61
AMZN
+0.86%
$235.24
HOOD
-4.60%
$122.57
IBRX
+10.79%
$2.36
PRPH
-5.55%
$0.19
RIG
+0.45%
$4.43
NWTN
-9.09%
$0.70
GRYP
-10.38%
$1.38
GOOGL
-0.87%
$317.36
NCT
-28.27%
$0.55
AMD
+0.99%
$219.68
MODV
-25.22%
$0.43
WULF
-0.85%
$15.37
RUBI
-11.59%
$0.14
PLTR
+0.13%
$168.68
SMR
+5.04%
$20.00
AG
+3.02%
$15.69
GRAB
-2.56%
$5.31
EXK
-4.28%
$9.50
T
+0.77%
$26.02
HBAN
+1.50%
$16.54
PLTD
+0.05%
$7.04
VHAI
-25.00%
$0.00
CRWV
+3.90%
$75.97
CPNG
-3.69%
$27.12
ITUB
-1.27%
$7.70
DVLT
-4.18%
$1.94
NFLX
+1.35%
$107.58
BAC
-0.18%
$53.55
APLD
+4.53%
$28.32
RGTI
-6.11%
$24.00
SAND
-6.04%
$12.12
BTE
+1.89%
$3.22
GPUS
-8.47%
$0.27
IREN
+0.37%
$47.99
HL
+5.32%
$16.82
VALE
+0.67%
$12.69
SHOT
-74.37%
$0.39
TE
+13.26%
$4.66
WBUY
+35.51%
$2.14
ZAPP
-46.30%
$0.15
CDE
-0.36%
$17.20
AAPL
+0.28%
$279.64
GOOG
-0.72%
$317.80
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.